Simon, V, Czobor, P, Bálint, S, Mészáros, A, Bitter, I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry
2009; 194: 204–11.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) . APA, 1994.
Biederman, J, Mick, E, Faraone, SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry
2000; 157: 816–8.
Kessler, RC, Adler, L, Ames, M, Barkley, RA, Birnbaum, H, Greenberg, P, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ
2005; 47: 565–72.
Hammerness, P, Surman, C, Miller, K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep
2008; 8: 484–9.
Rosler, M, Casas, M, Konofal, E, Buitelaar, J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry
2010; 5: 684–98.
Eme, RF. Attention-deficit/hyperactivity disorder and correctional health care. J Correct Health Care
2009; 5: 5–18.
Ginsberg, Y, Hirvikoski, T, Lindefors, N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry
2010; 10: 112.
Rosler, M, Retz, W, Retz-Junginger, P, Hengesch, G, Schneider, M, Supprian, T, et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci
2004; 254: 365–71.
Young, SJ, Adamou, M, Bolea, B, Gudjonsson, G, Muller, U, Pitts, M, et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statment from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry
2011; 11: 32.
Gudjonsson, GH, Wells, J, Young, S. Personality disorders and clinical syndromes in ADHD prisoners. J Atten Disord
Young, S, Wells, J, Gudjonsson, G. Predictors of offending among prisoners: the role of attention-deficit hyperactivity disorder and substance use. J Psychopharmacol
National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE, 2009 (http://guidance.nice.org.uk/CG72/NICEGuidance/).
Faraone, SV, Spencer, T, Aleardi, M, Pagano, C, Biederman, J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol
2004; 24: 24–9.
Koesters, M, Becker, T, Kilian, R, Fegert, JM, Weinmann, S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol
2009; 23: 733–44.
Adler, LA, Spencer, T, McGough, JJ, Jiang, H, Muniz, R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord
2009; 12: 449–59.
Bejerot, S, Ryden, EM, Arlinde, CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry
Rösler, M, Fischer, R, Ammer, R, Ose, C, Retz, W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci
2009; 259: 120–9.
Wender, PH, Reimherr, FW, Marchant, BK, Sanford, ME, Czajkowski, LA, Tomb, DA. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord
2010; 15: 36–45.
Lobbestael, J, Leurgans, M, Arntz, A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother
2010; 18: 75–9.
Hare, RD, Clark, D, Grann, M, Thornton, D. Psychopathy and the predictive validity of the PCL-R: an international perspective. Behav Sci Law
2000; 18: 623–45.
Rosler, M, Retz, W, Stieglitz, RD. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations – benchmarking instruments for international multicentre trials. Pharmacopsychiatry
2010; 43: 92–8.
Guy, W. Clinical Global Impressions. US Department of Health and Human Services, 1976.
Ramirez, A, Ekselius, L, Ramklint, M. Axis V – Global Assessment of Functioning scale (GAF), further evaluation of the self-report version. Eur Psychiatry
2008; 23: 575–9.
Medori, R, Ramos-Quiroga, JA, Casas, M, Kooij, JJ, Niemela, A, Trott, GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry
2008; 63: 981–9.
Spencer, T, Biederman, J, Wilens, T, Doyle, R, Surman, C, Prince, J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry
2005; 57: 456–63.
Surman, CB, Monuteaux, MC, Petty, CR, Faraone, SV, Spencer, TJ, Chu, NF, et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J Clin Psychiatry
2010; 71: 1612–6.
Buitelaar, JK, Kooij, JJ, Ramos-Quiroga, JA, Dejonckheere, J, Casas, M, van Oene, JC, et al. Predictors of treatment outcome in adults with ADHD treated with OROS methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry
2011; 35: 554–60.
Levin, FR, Evans, SM, Brooks, DJ, Kalbag, AS, Garawi, F, Nunes, EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend
2006; 81: 37–48.